Dose-Dependent Silibinin Modulates Estrogen Receptor 1 and LINC RNA 00511 in Breast/Endometrial Cancer Cells
DOI:
https://doi.org/10.58600/eurjther3011Keywords:
breast cancer, endometrial cancer, estrogen receptor 1, long intergenic non-coding RNA 00511, silibinin, phytoestrogenAbstract
Objective: Estrogen receptor–positive (ER+) breast and endometrial cancers are driven by estrogen-responsive transcriptional networks involving estrogen receptor 1 (ESR1) and regulatory long non-coding RNAs. We investigated the dose-dependent effects of silibinin on cell behavior and ESR1/long intergenic non-coding RNA 00511 (LINC00511) expression in ER+ cancer cell models.
Methods: MCF-7 breast cancer cells and Ishikawa endometrial cancer cells were exposed to graded concentrations of silibinin. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, wound closure by scratch (wound-healing) assay, and apoptosis by Annexin V/propidium iodide (PI) staining. ESR1 and LINC00511 transcript levels were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Half-maximal inhibitory concentration (IC50) values were calculated from viability data.
Results: Lower silibinin concentrations increased cell viability and wound closure and were accompanied by higher ESR1 and LINC00511 expression. In contrast, higher concentrations suppressed ESR1 and LINC00511, reduced wound closure, and increased apoptosis. The IC50 values were 193 µM for MCF-7 cells and 263 µM for Ishikawa cells.
Conclusion: Silibinin elicited a biphasic, dose-dependent response in ER-positive breast and endometrial cancer cells. These findings suggest that the biological effects of silibinin in ER-positive tumor models should be interpreted in a dose-dependent context.
References
[1] Hutchinson L (2010) Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol. 7(12):669–670. https://doi.org/10.1038/nrclinonc.2010.192
[2] Rodriguez AC, Blanchard Z, Maurer KA, Gertz J (2019) Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm Cancer. 10(2-3):51-63. https://doi.org/10.1007/s12672-019-0358-9
[3] Liang J, Shang Y (2013) Estrogen and cancer. Annu Rev Physiol. 75:225–240. https://doi.org/10.1146/annurev-physiol-030212-183708
[4] Porras L, Gougelet A, Marzi L, Besseau L, Deblois G (2021) Positive regulation of estrogen receptor alpha in breast tumorigenesis. Cells. 10(11):2966. https://doi.org/10.3390/cells10112966
[5] Dustin D, Gu G, Fuqua SA (2019) ESR1 mutations in breast cancer. Cancer. 125(21):3714–3728. https://doi.org/10.1002/cncr.32345
[6] Barrett-Connor E, Stuenkel CA (2001) Hormone replacement therapy (HRT)—risks and benefits. Int J Epidemiol. 30:423–426. https://doi.org/10.1093/ije/30.3.423
[7] The North American Menopause Society (2012) The 2012 hormone therapy position statement of The North American Menopause Society. Menopause. 19(3):257–271. https://doi.org/10.1097/gme.0b013e31824b970a
[8] Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X (2020) Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. J Cancer. 11(7):1693–1701. https://doi.org/10.7150/jca.41943
[9] Lumachi F, Santeufemia DA, Basso SM (2015) Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 6(3):231–239. https://doi.org/10.4331/wjbc.v6.i3.231
[10] Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest. 116(3):561–570. https://doi.org/10.1172/JCI27987
[11] Theodorou V, Stark R, Menon S, Carroll JS (2013) GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 23(1):12–22. https://doi.org/10.1101/gr.139469.112
[12] Lei JT, Gou X, Seker S, Ellis MJ (2019) ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat. 5(1):38. https://doi.org/10.20517/2394-4722.2019.12
[13] Kung JT, Colognori D, Lee JT (2013) Long noncoding RNAs: past, present, and future. Genetics. 193:651–669. https://doi.org/10.1534/genetics.112.146704
[14] Prensner JR, Chinnaiyan AM (2011) The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. https://doi.org/10.1158/2159-8290.CD-11-0209
[15] Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med. 21(11):1253–1261. https://doi.org/10.1038/nm.3981
[16] Peng WX, Koirala P, Mo YY (2017) LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36(41):5661–5667. https://doi.org/10.1038/onc.2017.184
[17] Wang K, Zhu G, Bao S, Chen S (2019) Long non-coding RNA LINC00511 mediates the effects of ESR1 on proliferation and invasion of ovarian cancer through miR-424-5p and miR-370-5p. Cancer Manag Res. 11:10807–10819. https://doi.org/10.2147/CMAR.S232140
[18] Zhang H, Zhao B, Wang X, Zhang F, Yu W (2019) LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci. 228:135–144. https://doi.org/10.1016/j.lfs.2019.04.063
[19] Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J (2019) Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. Genome Res. 29:1429–1441. https://doi.org/10.1101/gr.244780.118
[20] Chen Z, Wu H, Zhang Z, Li G, Liu B (2019) LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int. 19:351. https://doi.org/10.1186/s12935-019-1070-0
[21] Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ (2016) Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids. 5:e385. https://doi.org/10.1038/mtna.2016.94
[22] Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, Qin A, Wang Y, Zhang Y, Chen C (2018) Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 37(1):289. https://doi.org/10.1186/s13046-018-0945-6
[23] Sirotkin AV, Harrath AH (2014) Phytoestrogens and their effects. Eur J Pharmacol. 741:230–236. https://doi.org/10.1016/j.ejphar.2014.07.057
[24] Patisaul HB, Jefferson W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol. 31:400–419. https://doi.org/10.1016/j.yfrne.2010.03.003
[25] Mostrom M, Evans T (2011) Phytoestrogens. In: Gupta RC (ed), Reproductive and Developmental Toxicology, 2nd edn. Academic Press, pp 707–722. https://doi.org/10.1016/B978-0-12-382032-7.10052-9
[26] Basu P, Maier C (2018) Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomed Pharmacother. 107:1648–1666. https://doi.org/10.1016/j.biopha.2018.08.100
[27] Rowe IJ, Baber RJ (2021) The effects of phytoestrogens on postmenopausal health. Climacteric. 24:57–63. https://doi.org/10.1080/13697137.2020.1863356
[28] Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R (2007) Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis. 28:2567–2574. https://doi.org/10.1093/carcin/bgm218
[29] Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC (2012) Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem. 113:1733–1743. https://doi.org/10.1002/jcb.24043
[30] Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3(6):1101–1108. https://doi.org/10.1038/nprot.2008.73
[31] Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS (2007) Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 354(1):165–171. https://doi.org/10.1016/j.bbrc.2006.12.181
[32] Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F (2016) Silibinin-induced apoptosis and downregulation of microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. J Breast Cancer. 19(1):45–52. https://doi.org/10.4048/jbc.2016.19.1.45
[33] Jen SH, Wei MP, Yin AC (2015) The combinatory effects of glabridin and tamoxifen on Ishikawa and MCF-7 cell lines. Nat Prod Commun. 10(9):1573–1576. https://doi.org/10.1177/1934578X1501000922
[34] Dupuis ML, Conti F, Maselli A, Pagano MT, Ruggieri A, Anticoli S, Fragale A, Gabriele L, Ruggieri S, Fiorucci G, Frati L, D’Adamo MC, Rosati E, Torrisi MR, Scambia G, Fattorossi A (2018) The natural agonist of estrogen receptor β silibinin plays an immunosuppressive role representing a potential therapeutic tool in rheumatoid arthritis. Front Immunol. 9:1903. https://doi.org/10.3389/fimmu.2018.01903
[35] Liu W, Ji Y, Sun Y, Si L, Fu J, Hayashi T, Murakami Y, Kitamura Y, Yanagihara K, Watanabe S, Fukuda M, Takahashi K (2020) Estrogen receptors participate in silibinin-caused nuclear translocation of apoptosis-inducing factor in human breast cancer MCF-7 cells. Arch Biochem Biophys. 689:108458. https://doi.org/10.1016/j.abb.2020.108458
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 İbrahim Uğur Çalış, Esin Sakallı Çetin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Funding data
-
Muğla Sıtkı Koçman Üniversitesi
Grant numbers 22/140/01/3/4
